FCCC LOGO Faculty Publications
Haddad RI , Nasr C , Bischoff L , Busaidy NL , Byrd D , Callender G , Dickson P , Duh QY , Ehya H , Goldner W , Haymart M , Hoh C , Hunt JP , Iagaru A , Kandeel F , Kopp P , Lamonica DM , McIver B , Raeburn CD , Ridge JA , Ringel MD , Scheri RP , Shah JP , Sippel R , Smallridge RC , Sturgeon C , Wang TN , Wirth LJ , Wong RJ , Johnson-Chilla A , Hoffmann KG , Gurski LA
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
J Natl Compr Canc Netw. 2018 Dec;16(12) :1429-1440
PMID: 30545990   
Back to previous list
Abstract
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Notes
1540-1413 Haddad, Robert I Nasr, Christian Bischoff, Lindsay Busaidy, Naifa Lamki Byrd, David Callender, Glenda Dickson, Paxton Duh, Quan-Yang Ehya, Hormoz Goldner, Whitney Haymart, Megan Hoh, Carl Hunt, Jason P Iagaru, Andrei Kandeel, Fouad Kopp, Peter Lamonica, Dominick M McIver, Bryan Raeburn, Christopher D Ridge, John A Ringel, Matthew D Scheri, Randall P Shah, Jatin P Sippel, Rebecca Smallridge, Robert C Sturgeon, Cord Wang, Thomas N Wirth, Lori J Wong, Richard J Johnson-Chilla, Alyse Hoffmann, Karin G Gurski, Lisa A Journal Article United States J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.